Tag Archives: healthcare

WindRose Health Investors Makes Investment in Avalon Healthcare Solutions

Franciso Partners

New York, NY, January 12, 2026 – WindRose Health Investors, LLC (“WindRose”), the New York-based healthcare private equity firm, announced that it has completed an investment in Avalon Healthcare Solutions (“Avalon” or the “Company”), a platform that integrates laboratory science and data to power real-time, lab-driven insights on behalf of health plan clients. Francisco Partners, a leading global investment firm that specializes in partnering with technology businesses, has also made an additional investment in the company. Avalon helps to ensure the appropriate use of routine and genetic lab tests and manages a national network of independent test providers.

WindRose’s investment and deep experience scaling tech-enabled payer services solutions will enable Avalon to accelerate its growth trajectory, invest in novel product offerings and further develop its next-generation technology platform. Avalon is uniquely positioned to address the complex and evolving needs of payers with its proprietary technology that automatically reviews and enforces lab test claims against client-adopted, clinically-derived policies. Avalon’s management team, headed by CEO Bill Kerr, will continue to lead the Company in its next phase of growth.

“We are grateful for Francisco Partners’ continued support and are excited to partner with WindRose and begin this next chapter,” said Mr. Kerr. “Francisco Partners has enabled us to grow and scale Avalon to where it is today, and we believe WindRose is a perfect additional partner to support the Company’s growth strategy of delivering an end-to-end lab benefit management platform. With the help of WindRose’s investment and strategic involvement, Avalon will continue to drive meaningful efficiencies on behalf of its health plan clients while also focusing on investing in innovation and building out its suite of capabilities.”

“Avalon has built a leadership position as a preferred partner to health plans that seek operational efficiencies while managing increasingly complex lab benefits. Avalon’s purpose-built lab insights platform uniquely combines lab benefits management, clinical science, and analytics to deliver value to its clients. We are thrilled to partner with Bill and the team to scale the business and continue to support product innovation,” said David Pontius, Partner at WindRose.

“Avalon has evolved into a differentiated, mission-critical partner for health plans by combining deep clinical expertise with a highly scalable technology platform,” said Ezra Perlman, Co-President of Francisco Partners. “We are excited to continue supporting Bill and the Avalon team as they invest in new product capabilities and drive meaningful impact for payers navigating an increasingly complex diagnostics landscape.”

William Blair acted as financial advisor to Avalon. McDermott Will & Schulte LLP acted as legal advisor to WindRose, Kirkland and Ellis acted as legal advisor to Francisco Partners and Davis Polk & Wardwell LLP acted as legal advisor to Avalon.

About WindRose Health Investors

New York City-based WindRose makes equity investments in companies that operate within the services sectors of the healthcare industry. The firm focuses on companies with profitable business models and a demonstrated ability to deliver cost-effective solutions. With approximately $7 billion under management, WindRose invests in companies throughout the United States. For more information, please email us at info@windrose.com.

About Francisco Partners

Francisco Partners is a leading global investment firm that specializes in partnering with technology and technology-enabled businesses. Since its launch over 25 years ago, Francisco Partners has invested in over 500 technology companies, making it one of the most active and longstanding investors in the technology industry. With over $50 billion in capital raised to date, the firm invests in opportunities where its deep sectoral knowledge and operational expertise can help companies realize their full potential. For more information on Francisco Partners, please visit www.franciscopartners.com.

About Avalon Healthcare Solutions

Headquartered in Tampa, Florida, Avalon is a healthcare technology company focused on managing the appropriate use of thousands of routine and genetic diagnostic laboratory tests on behalf of health plan clients. Avalon’s library of evidence-based lab policies is actively managed by a team of scientists and encoded into its proprietary platform to help payers reduce avoidable costs and improve clinical outcomes. For more information, please visit www.avalonhcs.com.

Contact:
Lambert by LLYC
Caroline Luz
cluz@lambert.com
203-570-6462

Categories: News

Tags:

EQT Life Sciences backs Kinaset Therapeutics’ USD103 million Series B to advance inhaled therapeutic for treatment of respiratory diseases

No Comments
EQT Life Science

EQT Life Sciences x Kinaset Therapeutics

  • EQT Life Sciences invests in U.S.-based Kinaset Therapeutics – a clinical-stage biopharma company developing a novel and differentiated inhaled therapeutic to treat serious respiratory diseases
  • Proceeds from the oversubscribed USD 103 million Series B round to help advance frevecitinib – a single-capsule dry powder inhaler delivering therapeutic lung concentrations, with the potential to treat the broad asthma population
  • EQT Life Sciences’ Daniela Begolo to join Kinaset Therapeutics’ Board of Directors

EQT Life Sciences is pleased to announce that the LSP 7 Fund has invested in Kinaset Therapeutics (the “Company”), a clinical-stage biopharmaceutical company based in Boston, U.S. developing a novel and differentiated inhaled therapeutic to treat serious respiratory diseases.

The investment was made as part of Kinaset’s oversubscribed USD 103 million Series B financing, led by RA Capital Management and Forge Life Science Partners, with participation from new investors EQT Life Sciences, Vivo, Schroders, Willett Advisors, Pictet, and Sixty Degree Capital, as well as existing investors Atlas Venture, 5AM Ventures, and Gimv.

Asthma affects millions of patients worldwide, yet a significant proportion remains inadequately controlled on existing therapies. Today’s biologic treatments mainly help patients with certain types of inflammation, leaving many with severe asthma without effective options. This has created a clear unmet need for broadly effective, safe, and inhaled anti-inflammatory therapies that can address the full spectrum of asthma disease.

Kinaset Therapeutics’s Series B will be used to help advance frevecitinib, a novel inhaled dry powder in development for patients with asthma that remains inadequately controlled by standard of care inhaled maintenance therapies. Frevecitinib is an inhaled pan-JAK inhibitor – an immune-modulating medication – designed to deliver therapeutic concentrations directly to the lungs via a single-capsule dry powder inhaler, while minimizing systemic exposure.
Daniela Begolo, Managing Director at EQT Life Sciences, who will join Kinaset’s Board of Directors, said: “Kinaset is taking a highly differentiated approach to asthma by pairing validated JAK biology with an inhaled delivery designed to maximize lung exposure while minimizing systemic risk. Backed by a strong and experienced management team, Kinaset has the potential to address a broad asthma population, including patients not well served by current therapies, making frevecitinib a particularly compelling program to advance into later-stage development.”

Robert Clarke, CEO of Kinaset Therapeutics, said: “Since day one, our goal has been to establish a best-in-class therapeutic for the treatment of severe inflammatory respiratory diseases. Critically, and unlike the majority of existing therapeutics, frevecitinib can provide benefit to all patients with severe asthma including those with a non-eosinophilic phenotype who continue to suffer from an absence of safe and effective therapies. This financing marks a significant milestone for Kinaset to execute our vision of advancing frevecitinib through a Phase 2 dose-ranging clinical study in severe asthma and potentially beyond. The participation of leading life science investors underscores both the strength of our team and the critical unmet need we aim to address.”

Contact
EQT Press Office, press@eqtpartners.com

Downloads

About EQT Life Sciences
EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences aims to back the smartest inventors who have ideas that could truly make a difference for patients.

More information: www.eqtgroup.com/private-capital/eqt-life-sciences

About Kinaset Therapeutics, Inc.
Kinaset Therapeutics is focused on developing inhaled therapeutics to address significant unmet medical needs in respiratory diseases. With founding investors 5AM Ventures, Atlas Venture and Gimv, the Company is pursuing a patient-focused approach to build a leading respiratory therapeutics company.

See more information at the Company’s website 

Categories: News

Tags:

819 Capital Partners acquires significant minority stake in RiverD

819 Capital Partners

Deventer, 5 January 2026 – 819 Capital Partners has acquired a significant minority participation in RiverD International. The investment, through 819 Evergreen Fund, is aimed at supporting RiverD’s long-term growth and development.

RiverD is a Dutch high-tech company developing and manufacturing advanced instruments for non-invasive molecular analysis of human skin and tissue using Raman spectroscopy. Its skin analysis technology enables real-time, reagentless measurement of skin tissue composition. RiverD’s other R&D-focus area is Raman-guided surgery based on fiber-optic technology.

The company’s solutions are used globally in medical and dermatological research, and cosmetic and pharmaceutical R&D.

RiverD was founded by Gerwin Puppels, who is widely regarded as one of the world’s leading experts in Raman spectroscopy and a pioneer in its application to biomedical research. As founder and CEO, he has been the driving force behind RiverD’s scientific vision, technological leadership, and international reputation.

The transaction reflects 819 Capital’s confidence in RiverD’s technology, market position, and long-term potential. Through the investment from the 819 Evergreen Fund, RiverD gains access to growth capital and strategic support to accelerate product development, international expansion, and further market adoption.

Categories: News

Tags:

With WA Beveiliging attracts Karmijn Kapitaal as growth partner for further growth within care security and public safety

Karmijn Kapitaal

Zeist, 5 january 2026 – Investor Karmijn Kapitaal is taking a majority stake in security organization Met WA Beveiliging. The Zeist-based company specializes in safety within care environments and community settings. The collaboration, which has been established under the guidance of Marktlink, is aimed at further growth in a consolidating market. Met WA Beveiliging and Karmijn Kapitaal want to realize growth through both organic growth and acquisitions.

Since 2016, Met WA has been providing security solutions in, among others, mental health care (GGZ), hospitals, youth care, reception locations and distribution centers. Security guards and Care & Safety employees work daily at locations where rapid signaling, maintaining calm and careful action are essential. In close collaboration with care professionals and other chain partners, they combine safety with practical support on the work floor, such as accompanying clients, supporting care providers and carrying out daily work activities within care institutions.

Own academy

Through its own Met WA Academy, employees receive practice-oriented training in, among other things, de-escalation, dealing with special behavior, risk management, aggression regulation and emergency response (BHV). This broad base makes teams deployable at diverse locations, from closed departments to the emergency room. The organization consists of 21 staff members and several hundred security professionals.

In recent years, Met WA expanded its field of work, among other things through the acquisition of the Nederlandse Veiligheidsgroep (NVG) in 2023. With this, in addition to care security, public safety also became a permanent part of the service provision.

Investment with positive social impact

Karmijn Kapitaal supports the further professionalization and growth of Met WA. As an investor, Karmijn focuses on SME companies with a positive social impact, among others within the themes of care and safety. “We have carefully prepared this step and consciously searched for a partner who shares our vision,” says founder Michiel Broeksma. “Together with Marktlink, we actively explored the market. In Karmijn Kapitaal, we have found the right party to further develop Met WA. This acquisition enables us to accelerate building a professional, scalable organization that is ready for the future.”

Karmijn underlines the distinctive character of the organization. “The need for safety in care and public domains continues to increase. At the same time, this requires different solutions than traditional security,” according to Nicole Zomerhuis of Karmijn Kapitaal. “Met WA offers a professional and people-oriented model that is scalable and broadly applicable. We are pleased to support the organization in increasing its positive impact on care and other social environments.”

Buy-and-build as growth path

The collaboration with Karmijn forms the starting point of a buy-and-build strategy. Met WA aims for targeted acquisitions of security companies within care, hospitality or public safety. “This transaction is a logical step within the consolidation wave in this sector,” says Jeffrey Scholtens, partner at Marktlink. “We see an increasing demand for security services that match the complexity of care and public environments, whereby tightened legislation and regulations around self-employed (zzp) constructions strengthen this demand. Met WA is a mature and distinctive player who is excellently positioned to play a central role in this dynamic. We facilitate the connection with parties that match the profile and ambitions of the organization through our network. Within the group that arises from this, the companies strengthen each other to become a leading player within (care) security.”

 

Categories: News

Tags:

Platinum Equity Completes Acquisition of Owens & Minor Products & Healthcare Services Business

Platinum

Two medical staff in full protective gear handle surgical instruments in a clinical setting, wearing masks, gowns, and bright green gloves. | Platinum Equity

P&HS anticipated to benefit from Platinum’s carve-out experience, sector expertise and commitment to growing the business

 P&HS will retain Owens & Minor brand and operate as a standalone company in Platinum’s portfolio

LOS ANGELES (Dec. 31, 2025) – Platinum Equity announced today that the acquisition of the Owens & Minor Products & Healthcare Services business (“Owens & Minor P&HS”) has been completed.

The transaction includes the Owens & Minor brand and the acquired business will continue to operate as Owens & Minor P&HS as a privately held standalone company in Platinum Equity’s portfolio.

The seller, which retained a five percent interest in the business, recently announced its remaining business will be rebranded Accendra Health, Inc., effective December 31, 2025.

Headquartered in Richmond, VA, Owens & Minor P&HS is a vertically integrated medical supply distribution platform primarily serving the acute care market. It is a leading national distributor of medical and surgical supplies for hospitals, health systems, and other healthcare providers across the United States.

“With our sector expertise, carve-out experience, and operational resources, we can help the company become an even more agile and responsive partner to the healthcare industry it serves. ”

Jacob Kotzubei, Co-President, Platinum Equity

“For more than 140 years, Owens & Minor has been guided by a strong sense of purpose, and we are proud to support its next chapter as a standalone business,” said Jacob Kotzubei, Co-President of Platinum Equity. “With our sector expertise, carve-out experience, and operational resources, we can help the company become an even more agile and responsive partner to the healthcare industry it serves. We will work with the company to strengthen its foundation, expand its capabilities, and ensure it continues delivering essential products and services when and where customers need them most.”

Platinum Equity has invested in numerous healthcare and supply chain businesses and has 30 years of experience acquiring and operating global businesses that have been part of large corporate entities. In recent years the firm has acquired businesses from firms like Caterpillar, Emerson Electric, Ingersoll Rand and Kohler, among others.

Platinum Equity Managing Director Matthew Louie said that continuity is critical to the transition process.

“Owens & Minor P&HS has a proud legacy of putting customers first, and we are excited to help carry that forward,” said Louie. “Our goal is to ensure continuity while making thoughtful improvements that keep the company dynamic, responsive, and aligned with the evolving needs of its customers. We will work closely with the team to help strengthen fulfillment performance, drive operational excellence across manufacturing and distribution, and accelerate growth in proprietary products. At the same time, we will invest in supply chain enhancements to help improve efficiency and resiliency.”

Bank of America and Fifth Third served as financial advisors to Platinum Equity on the P&HS acquisition. Gibson, Dunn & Crutcher LLP served as legal advisor, Willkie Farr & Gallagher LLP served as debt financing counsel, and Latham & Watkins LLP served as special regulatory counsel to Platinum Equity on the transaction.

Citi and Wells Fargo acted as financial advisors to Owens & Minor. Kirkland & Ellis served as Owens & Minor’s legal advisor.

About Platinum Equity

Founded in 1995 by Tom Gores, Platinum Equity is a global investment firm with approximately $50 billion of assets under management and a portfolio of approximately 60 operating companies that serve customers around the world. Platinum Equity specializes in mergers, acquisitions and operations – a trademarked strategy it calls M&A&O® – acquiring and operating companies in a broad range of business markets, including manufacturing, distribution, transportation and logistics, equipment rental, metals services, media and entertainment, technology, telecommunications and other industries. Over the past 30 years Platinum Equity has completed more than 500 acquisitions

Published: Friday, January 2, 2026 | Updated: Friday, January 2, 2026

Categories: News

Tags:

HBox Receives Strategic Growth Investment from Charlesbank Technology Opportunities Fund

Charlesbank

Boston, MA – December 19, 2025: HBox (“HBox” or the “Company”), a leading virtual care platform for specialty practices, announced that it has received a growth investment from Charlesbank’s Technology Opportunities Fund (“TOF”) II. Amid rising chronic disease prevalence, expanding reimbursement for outcome-focused virtual care and innovative new ways for treating patients between visits, specialty practices are seeking scalable ways to extend treatment beyond the clinic. Charlesbank’s investment provides capital to help HBox advance key initiatives, including expanding its virtual care capabilities, furthering its mission to transform care delivery for patients with high-risk chronic conditions, and positioning itself as the virtual care partner to the specialty practice of the future. The transaction closed on December 17, 2025.

HBox is led by BanuPrasad Dhanakoti (Chief Executive Officer), Sandeep Subramanya (Chief Operating Officer) and Mohammed Ali (Chief Revenue Officer), who co-founded the Company. HBox delivers an integrated, AI-powered virtual care platform that leverages connected medical devices, next-generation patient-engagement tools and care services that create a virtual clinic within a clinic, enabling cardiology, pulmonology, nephrology and other specialty clinics to continue care seamlessly outside of in-person care settings. HBox aggregates real-time vitals, patient actions and clinical documentation into a unified system that allows physicians to efficiently manage large chronic populations while maintaining high-touch patient care.

“Today marks an important step forward for HBox and for the patients and clinicians we support,” said Banu Dhanakoti. “For cardiac patients in particular, timely monitoring and personalized care plans can help prevent hospitalizations and provide families with greater confidence in day-to-day condition management. With Charlesbank’s TOF team behind us, we can continue strengthening our offering and advancing a virtual care model that seeks to bring the cardiology clinic of the future into today’s specialty practices – enhancing quality and continuity of care without adding burden to clinics.”

Since its founding, HBox has delivered a fast pace of innovation and high service quality to customers, resulting in rapid customer growth and high patient compliance rates. Today, HBox is a mission-critical partner to independent specialty practices across the country.

“Preventative, virtual and continuous care is the future of healthcare for both improving outcomes and managing costs,” said Michael Zirngibl, Principal at Charlesbank. “We are excited to back Banu, Sandeep, Mo and the team as they continue to expand HBox’s innovative virtual ‘clinic within a clinic’ offering.”

“Remote monitoring and virtual care are becoming standard in many specialties, yet most practices lack the technology and staff to run these programs on their own,” added Hiren Mankodi, Co-Head of Charlesbank’s Technology Opportunities team. “HBox’s combination of software, services and specialty focus positions the Company to be that infrastructure at scale.”

Kaizen Equity Partners served as exclusive financial advisor to HBox, with K&L Gates serving as its counsel. Brown Gibbons Lang & Company served as financial advisor to Charlesbank, with Mintz and McDermott Will & Schulte as counsel.

Categories: News

Tags:

EQT portfolio company Colisée to change ownership

eqt

Colisée (“the Company”), a European private-sector provider of support and care for the elderly, today announced the signing of a lock-up agreement as part of a financial recapitalization plan led by its lenders, resulting in a transition of ownership. As part of this process, EQT Infrastructure V (“EQT”) and other shareholders are expected to exit their position.

EQT acquired a majority stake in Colisée in 2020. At the time, EQT was attracted by the Company’s strong focus on quality of care and the opportunity to grow the business while upholding its best-in-class standards.

During EQT’s ownership, Colisée expanded from 270 to almost 400 facilities. EQT supported significant investments in staff training, facility maintenance, digital systems and other initiatives to improve the quality of care and services. The Company also accelerated its sustainability efforts, becoming the first nursing home operator in France to adopt the status of entreprise à mission and introducing rigorous quality evaluation and monitoring frameworks, resulting in validated near-term Science Based Targets.

Despite revenue growth since EQT’s acquisition, Colisée has faced margin deterioration since 2022, driven by several market-related headwinds and operational challenges. In response, EQT worked closely with Colisée’s management to implement a performance improvement plan, followed by the initiation of a recapitalization plan aimed at achieving a sustainable capital structure.

Throughout, EQT’s priority has been to partner with the Company to ensure a solid foundation, and to safeguard the continuity of operations and quality of care for residents. While EQT had put forward a proposal that aimed to deliver stability and sustainability across the capital structure with significant new equity, Colisée’s lenders have decided to impose their own plan. The recapitalization plan announced today will result in EQT exiting its position in Colisée.

Arnaud Marion, CEO of Colisée, said: “Colisée sincerely thanks EQT for its role as a responsible and highly committed lead shareholder throughout its ownership in Colisée and during the recapitalization process of the Company. Today, Colisée is well-positioned to achieve strong and sustainable performance over the coming years while ensuring we continue to provide market-leading service to our residents.”

The legal and technical implementation of the contemplated recapitalization plan is expected to take several months.

Contact
EQT Press Office, press@eqtpartners.com

Downloads

About EQT
EQT is a purpose-driven global investment organization with EUR 267 billion in total assets under management (EUR 139 billion in fee-generating assets under management) as of 30 September 2025, within two business segments – Private Capital and Real Assets. EQT owns portfolio companies and assets in Europe, Asia Pacific and the Americas and supports them in achieving sustainable growth, operational excellence and market leadership.

More info: www.eqtgroup.com
Follow EQT on LinkedIn, X, YouTube and Instagram

Categories: News

Tags:

Bure divests holding in Mentice

Bure

Bure Equity AB (publ) (“Bure”) has signed an agreement to divest 4,037,824 shares in Mentice AB (publ), listed on Nasdaq First North Growth Market.

The buyer is Gulf Offshore Limited, a company controlled by the Howell family, which is currently the main owner of Mentice.

Following the transaction, Bure’s holding of shares in Mentice amounts to 100,000. Bure’s remaining holding secures Bure’s issued call options in Mentice.

 

Henrik Blomquist, CEO
henrik.blomquist@bure.se
Telephone: +46 (0) 8-614 00 20

Categories: News

Tags:

FamilyWell Health Announces $8M Series A Funding to Accelerate Nationwide Expansion of Integrated Women’s Mental Health Care

.406 Ventures

Building on its success in maternal mental health, funding will accelerate FamilyWell’s growth into menopause care, advance its AI-enabled digital platform, and scale the FamilyWell Academy provider training programs

 

BOSTON, Nov. 18, 2025 (GLOBE NEWSWIRE) — FamilyWell Health, the leading integrated women’s mental health company, today announced the closing of $8 million in Series A financing led by New Markets Venture Partners, with participation from existing and new investors – .406 Ventures, GreyMatter Capital, The Alix Foundation, The Donna Fund, and The Lee Foundation. This funding will accelerate FamilyWell’s national expansion, bringing its proven maternal mental health model to health systems, clinics, and payers across the country. It will also advance the company’s AI capabilities to broaden access, drive growth into perimenopause and menopause care, and scale its provider training programs through the FamilyWell Academy.

Women’s mental health remains one of healthcare’s most underserved and fastest-growing areas of need:

Founded in 2022 by Dr. Jessica Gaulton, a practicing physician at Harvard and survivor of postpartum depression, FamilyWell embeds virtual women’s mental health services—care coordination, coaching, therapy, and psychiatry—directly into clinics and health systems. Patients are connected to care within 24 hours and supported by a specialized team of providers. Through its integrated perinatal mental health program, 1 in 4 pregnant patients are referred to FamilyWell, with 95% of patients experiencing clinical improvement by four months. In addition, the model alleviates provider burden, while enabling clinics to capture untapped revenue from payers directly.

FamilyWell currently operates in Massachusetts, New Hampshire, Connecticut, Illinois, and Texas covering over 200,000 lives nationwide. The company has also recently partnered with one of the country’s largest managed care organizations, expanding access to insurance-covered coaching, therapy, and psychiatry for more women and birthing people across the country.

“FamilyWell is an ideal fit for New Markets’ mission to invest in evidence-based solutions that improve lives and expand access to life-saving care,” said Mark Grovic, General Partner and Founder, New Markets Venture Partners. “By integrating proven women’s mental health care into everyday clinical workflows, FamilyWell reduces suffering, strengthens family well-being, and helps parents return to work and thrive.”

Expansion Into Perimenopause and Menopause
Today, more than 50 million U.S. women are in perimenopause and up to 70% experience mental health symptoms such as anxiety, depression, insomnia, and cognitive changes. To meet the strong demand from its OB/GYN partners, FamilyWell has extended its integrated care model to support women through perimenopause and menopause. With this expansion, FamilyWell now supports women throughout the reproductive lifecycle, from fertility through menopause.

“What FamilyWell has built is more than a product—it’s a movement toward the care women and families deserve,” said Dr. Neel Shah, MD, MPP, Chief Medical Officer, Maven Clinic and Board Member, FamilyWell Health. “By embedding mental health care directly into the OB/GYN clinic, FamilyWell is scaling empathy as effectively as technology. Their proven model meaningfully improves patient outcomes—helping women reclaim their well-being and dignity during some of life’s most challenging transitions.”

Learn more about FamilyWell’s menopause offering:
https://www.familywellhealth.com/perimenopause

FamilyWell Academy
The FamilyWell Academy is training the next generation of women’s mental health providers to meet the nation’s growing need for specialized, reproductive mental health care. The company’s Perinatal Behavioral Health and Peri-/Menopause Behavioral Health certification programs equip coaches with the skills to deliver evidence-based, compassionate care—and help close the provider workforce gap.

“The mental health needs of women have been overlooked for far too long,” said Dr. Jessica Gaulton, founder and CEO of FamilyWell Health. “This capital enables us to expand our integrated care model, accelerate AI innovation, and deepen collaborations that make timely, high-quality support possible. Through the FamilyWell Academy and together with our OB/GYN partners, we’re reshaping the standard of care and addressing one of the most critical health crises facing women today.”

About FamilyWell Health
FamilyWell Health is transforming women’s mental health across the reproductive journey, from fertility through menopause and beyond. We embed evidence-based, insurance-covered mental health care directly into women’s health practices and health systems. By seamlessly integrating a virtual team of care managers, coaches, therapists, and psychiatric providers into clinical workflows, FamilyWell is improving patient outcomes and reducing medical provider workloads. Through the FamilyWell Academy, we are educating the next generation of women’s mental health providers to solve the growing workforce gap. Learn more at familywellhealth.com and follow us on LinkedIn and Instagram.

Media Contact:

press@familywellhealth.com

Categories: News

Tags:

Gimv joins forces with CNP to accelerate the global expansion of Equine Care Group

GIMV

  • European listed private equity investor Gimv and Belgian family-owned investor CNP announce the signing of definitive agreements under which Gimv will acquire an indirect minority stake in Equine Care Group (ECG) from CNP, which will remain ECG’s lead strategic partner.

  • By joining CNP, Bencis, the founders, managers and the veterinarians, Gimv becomes part of a very strong shareholder base united behind one ambition: to accelerate ECG’s development into the world’s leading one-stop partner for high-quality equine medicine, and to reinforce ECG’s position as the global leader for veterinary innovation, welfare, and professional excellence.

Created in 2021 by merging Dr. Tom Mariën’s leading equine clinic EquiTom, Global Medics, and Dr. Frederik Bruyninx’s Ambulatory Care practice, Equine Care Group  has evolved into a leading European provider of high-quality equine care. ECG offers equine hospitals, ambulatory veterinary services, reproductive solutions, nutrition and supplement brands and specialized laboratories. Known for partnering with Olympic teams and leading stud farms, ECG treats over 50,000 horses annually and has grown quickly through organic expansion and 30+ acquisitions.

Following the partnership announcement between CNP and ECG earlier this year, Gimv now joins through a joint entity that will retain majority ownership, with CNP as lead strategic partner. Gimv is committed to further support ECG’s global expansion alongside CNP and CEO Dr. Tom Mariën.  ECG’s vet-led unique holistic model brings together leading veterinarians and other equine healthcare professionals, invests in greenfield hospitals in regions lacking access and focuses on research, education and innovation, all with the clear goal of delivering the best possible medical care and improving horse welfare worldwide.

With the combined support of CNP, Bencis and now Gimv, ECG is well-positioned to cement its leadership in global equine healthcare, leveraging Belgium’s deep equestrian tradition and ECG’s international reputation for excellence and sustainability.

Bart Diels, Managing Partner – Head of Healthcare at Gimv: “As a team with a strong track record in doctor-led healthcare growth stories, we see clear parallels between ECG and our previous healthcare success stories. We are excited to support CNP and ECG’s management in accelerating the group’s international expansion and innovation in equine care.”

Xavier Le Clef & David Caudron – respectively CEO and CFO at CNP: “We are pleased to welcome Gimv as a minority investor, supporting ECG’s international growth. Gimv’s healthcare expertise complements CNP’s ambition and reinforces our shared mission to deliver world-class equine care and make this available all over the world.”

Dr. Tom Mariën & Julie Santens – respectively CEO and Managing Director at ECG: “We are delighted to welcome Gimv into our team. We share the same values, the same DNA and the same ambition. This partnership strengthens our foundations, and Gimv’s renowned healthcare expertise will help us to further professionalize our company and our sector.  Together we will raise the standards of equine veterinary care while preserving our veterinarian-led model.”

This investment supports Gimv’s ambition to become a leading European private equity investor and makes ECG one of its ten largest holdings.

Categories: News

Tags: